Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients.

[1]  A. Giménez-Arnau,et al.  Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria , 2017, Allergy.

[2]  Michihiro Hide,et al.  The EAACI/GA 2 LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update , 2015 .

[3]  M. Maurer,et al.  The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. , 2015, The Journal of allergy and clinical immunology.

[4]  T. Zuberbier,et al.  The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. , 2014, Allergy.

[5]  M. Maurer,et al.  Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. , 2014, Journal of dermatological science.

[6]  T. Casale,et al.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013, The New England journal of medicine.

[7]  Y. Okayama,et al.  Most Highly Cytokinergic IgEs Have Polyreactivity to Autoantigens , 2012, Allergy, asthma & immunology research.

[8]  S. Spector,et al.  A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. , 2011, The Journal of allergy and clinical immunology.

[9]  K. Schäkel,et al.  Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. , 2011, The Journal of allergy and clinical immunology.

[10]  E. Sabo,et al.  Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients , 2004, Allergy.